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Abbreviations: AGPATs, 1-acylglycerol-3-phosphate-O-acyltransferases; BBB, blood-
brain barrier; CDP, cytidine diphosphate; CerPCho, ceramide phosphocholine or 
sphingomyelin; DAG, diacylglycerol; DHA, docosahexaenoic acid; CoA, coenzyme A; 
Ins, inositol; LPLATs, lysophospholipid acyltransferases; LysoPtdCho, 
lysophosphatidylcholine; LysoPtdCho-14C-DHA, lysoPtdCho-DHA radiolabelled with 
carbon 14 [1-14C]; LysoPtdEtn, lysophosphatidylethanolamine; LysoPtdIns, 
lysophophatidylinositol; LysoPtdOH, lysophosphatidic acid; LysoPtdSer, 
lysophosphatidylserine; Mfsd2a, major facilitator superfamily domain-containing protein 
2; NE, non-esterified; NE-14C-DHA, NE-DHA radiolabelled with carbon 14 [1-14C]; 
PlsCho, plasmenylcholine; PlsEtn, plasmenylethanolamine; PtdCho, phosphatidylcholine; 
PtdEtn, phosphatidylethanolamine; PtdIns, phosphatidylinositol; PtdOH, phosphatidic 
acid; PtdSer, phosphatidylserine; PSS, phosphatidylserine synthase; TAG, 
triacylglycerol.  
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Abstract 
Recent studies suggest that at least two pools of plasma docosahexaenoic acid (DHA) can 
supply the brain: non-esterified DHA (NE-DHA) and lysophosphatidylcholine 
(lysoPtdCho)-DHA. In contrast to NE-DHA, brain uptake of lysoPtdCho-DHA appears to 
be mediated by a specific transporter, but whether both forms of DHA supply undergo the 
same metabolic fate, particularly with regards to enrichment of specific phospholipid 
(PL) subclasses, remains to be determined. This study aimed to evaluate brain uptake of 
NE-DHA and lysoPtdCho-DHA into brain PL classes. Fifteen-week old rats were infused 
intravenously with radiolabelled NE-14C-DHA or lysoPtdCho-14C-DHA (n = 4/group) 
over five mins to achieve a steady-state plasma level. PLs were extracted from the brain 
and separated by thin layer chromatography and radioactivity was quantified by liquid 
scintillation counting. The net rate of entry of lysoPtdCho-DHA into the brain was 
between 62% and 85% lower than the net rate of entry of NE-DHA, depending on the PL 
class. The proportion of total PL radioactivity in the lysoPtdCho-14C-DHA group 
compared to the NE-14C-DHA group was significantly higher in choline 
glycerophospholipids (ChoGpl) (48% vs 28%, respectively) but lower in ethanolamine 
glycerophospholipids (EtnGpl) (32% vs 46%, respectively). In both groups, radioactivity 
was disproportionally high in phosphatidylinositol and ChoGpl but low in 
phosphatidylserine and EtnGpl compared to the corresponding DHA pool size. This 
suggests that DHA undergoes extensive PL remodeling after entry into the brain. 
Keywords: Brain; docosahexaenoic acid; lysophosphatidylcholine; phosphatidylcholine; 
phosphatidylethanolamine; phosphatidylserine.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
4 
 
1. Introduction 
The brain has a unique fatty acid (FA) profile compared to other organs and 
tissues. It is highly enriched in docosahexaenoic acid (DHA), an omega-3 
polyunsaturated FA that cannot be synthesised de novo in mammals [1]. DHA is 
important for brain function including for neurodevelopment, neuronal transmission and 
integrity, maintaining membrane fluidity and the regulation of neuroinflammation [2-5]. 
In the human brain, more than 98% of DHA is esterified to phospholipid (PL), with 
approximately 65% of DHA found in ethanolamine glycerophospholipids (EtnGpl), 27% 
in phosphatidylserine (PtdSer), and less than 10% in choline glycerophospholipids 
(ChoGpl) and phosphatidylinositol (PtdIns) [6]. Relative to other FAs, DHA is highly 
enriched in the PtdSer pool with as much as 60% of PtdSer species containing at least one 
DHA molecule [7]. DHA esterified to PtdSer is believed to play a crucial role in neuronal 
growth and survival [7, 8].  
While the unique brain PL distribution of DHA has been extensively reported, 
less is known about how DHA is transported to the brain. There are at least two plasma 
pools that may supply the brain with DHA: the non-esterified (NE) pool and the 
lysophosphatidylcholine (lysoPtdCho) pool [9]. Previous studies by our group have 
shown that the major pool of DHA that supplies the brain is the NE pool with a rate of 
uptake approximately 10-fold higher than that of the lysoPtdCho pool [9]. However, it is 
currently unknown whether these two plasma DHA pools enrich the brain PL classes 
differently and this could have important consequences for targeting specific PL of the 
brain. Therefore, using an in vivo model, the objective of this study was to evaluate 
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whether plasma lysoPtdCho-DHA preferentially targets specific PL classes of the brain 
compared to NE-DHA.  
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2. Methods 
This study is a secondary analysis of our previous report [9]. The animal 
experimental protocol was approved by the Animal Ethics Committee of the University 
of Toronto. Ten-week old male Sprague Dawley rats were purchased from Charles Rivers 
(Saint-Constant, Qc, Canada) and were fed ad libitum with standard chow (Teklad 2018, 
Harlan, Madison, WI, USA) for five weeks until the start of the experimental procedure. 
2.1. DHA radiotracers 
 The DHA tracers were radiolabelled on the carboxyl carbon of the DHA molecule 
[1-14C] (NE-14C-DHA and 1-docosahexaenoyl-2-lysophosphocholine or lysoPtdCho-14C-
DHA). NE-14C-DHA was purchased from Moravek Biochemical Inc. (Brea, CA, USA) 
and lysoPtdCho-14C-DHA was purchased from American Radiolabeled Chemicals Inc. 
(St-Louis, MO, USA). NE-14C-DHA and lysoPtdCho-14C-DHA specific activity was 58 
mCi/mmol and 55 mCi/mmol, respectively. The NE-14C-DHA and lysoPtdCho-14C-DHA 
perfusates were solubilised in a 5 mM HEPES buffer containing bovine serum albumin to 
concentrations of 86 µci/ml. 
2.2. Intravenous radiotracer infusion 
 At the age of 15 weeks, rats were anaesthetised with isoflurane (3% induction and 
1-2% maintenance) and underwent surgery to implant catheters in the right carotid artery 
and right jugular vein as described previously [10]. The catheters were accessible from 
the back of the rat through a skin buttons sutured subcutaneously at the scapula. Rats 
were intravenously (iv) infused with 10 µCi of NE-14C-DHA or lysoPtdCho-14C-DHA in 
the jugular vein over five mins to achieve a plasma steady-state level as described 
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previously [11]. Thereafter, the rats were euthanized by head-focused high-energy 
microwave irradiation (13.5kW for 1.6 secs; Cober Electronics Inc., Norwalk, CT, USA). 
Brains were extracted and stored at -80 °C for biochemical analyses. 
2.3. Lipid extraction, PL class separation, and FA quantification 
 Whole brain total lipids were extracted according to a modified version of the 
Folch et al. method [12] with the use of chloroform : methanol : 0.88% KCl (2:1:0.75, by 
volume). Phospholipid class separation was performed using thin layer chromatography 
(TLC). Briefly, TLC-H plates (Analtech, Newark, DE, USA) were washed in chloroform 
methanol (2:1, by volume) the day prior to the TLC. From the brain total lipid extract 
(2000 µl), 250 µl was used for radioactivity counting and 100 µl was used for FA 
analyses. Samples were loaded on 7 cm wide lanes and migrated to achieve PL class 
separation with the following migration solvent: chloroform : methanol : 2-propanol : 
0.25% KCl : triethylamine (30:9:25:6:18, by volume). PL classes were revealed by 
spraying 0.1% 8-anilino-1-naphthalene sulfonic acid and visualised under UV light. PL 
were scraped for radioactivity analyses by liquid scintillation counting or methylated with 
14% (v/v) boron trifluoride methanol for 1h at 90ºC for gas chromatography FA analyses. 
Di-17:0 phosphatidylcholine (PtdCho) (Avanti Polar lipids Inc., Alabaster, AL, USA) was 
added as an external standard prior to methylation for brain FA quantification. FA methyl 
esters (FAME) were quantified on a Varian 430 gas chromatograph (Bruker, Billerica, 
MA, USA) equipped with a SP-2560 biscyanopropyl siloxane, capillary column (100 m 
length x 0.25 mm diameter x 0.2 µm film thickness; Supelco, Bellefonte, PA, USA). 
Helium was the carrier gas and 1 µl of samples were injected in splitless injection mode 
at 250ºC. The gas chromatograph temperature program was: 60ºC for 2 mins followed by 
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a 10°C/min ramp to 170°C with a 4 min hold, a 6.5°C/min ramp to 175°C, a 2.6°C/min 
ramp to 185°C, a 1.3°C/min ramp to 190°C and a 8.0°C/min ramp to 240°C with a 11 
min hold for a total run time of 42.7 mins. FAME were quantified by flame ionisation 
detection and the peaks were identified through comparison with an external mixed 
FAME standard (GLC-569, Nu Chek Prep Inc., Elysian, MN, USA). Plasma NE-DHA 
and lysoPtdCho-DHA concentrations were quantified by liquid chromatography tandem 
mass spectrometry and obtained from our previous report [9]. 
2.4. Plasmalogen separation and DHA quantification 
For this procedure, 150 µl of the brain total lipid extract (2000 µl) was used for 
radioactivity counting and 100 µl was used for DHA quantification. Phospholipid classes 
were separated on a TLC-H plate and revealed by UV light as described in section 2.3. 
Plasmalogens were separated from the ChoGpl and EtnGpl fractions by acidic hydrolysis 
as described previously [13, 14]. Briefly, the bands corresponding to ChoGpl and EtnGpl 
were scraped and phospholipids were extracted from the silica using 3 ml of Hexane : 
isopropanol  (3:2, by volume) containing 5.5 % water. Phospholipids were dried down 
under nitrogen and thereafter exposed to concentrated HCL vapors for 15 mins to 
hydrolyze the vinyl ether linkage of the plasmalogens [14]. The lipid mixture was then 
reconstituted in 100 µl of ChCl3 and separated on a second TLC-H plate using the same 
parameters as in section 2.3. The bands corresponding to plasmenylcholine (PlsCho), 
PtdCho, plasmenylethanolamine (PlsEtn), and PtdEtn were scraped for radioactivity 
analyses by liquid scintillation counting or extracted from the silica using 3 ml of Hexane 
: isopropanol  (3:2, by volume) containing 5.5 % water. The extracted lipids were 
thereafter hydrolysed to remove the carrier group from the FAs, dried down under a 
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stream of nitrogen and derivatized to pentafluorobenzyl (PFB) esters, as previously 
described [15, 16]. FA PFB esters were quantified on an Agilent 5977A quadrupole mass 
spectrometer coupled to an Agilent 7890B gas chromatographer (Agilent Technologies, 
Mississauga, ON, Canada) in negative chemical ionization mode. Graded concentrations 
of Di-17:0 PtdCho were hydrolysed and derivatized to FA PFB esters in parallel to 
produce the standard curve for DHA quantification. FA PFB esters were injected via an 
Agilent 7693 autosampler into a DB-FFAP 30 m x 0.25 mm i.d. x 25 µm film thickness 
capillary column (J&W Scientific from Agilent Technologies, Mississauga, ON, Canada) 
interfaced into the ion source with helium as the carrier gas. 
2.5. Liquid scintillation counting and kinetics calculations 
 Brain PL classes and plasma NE-FA and lysoPtdCho-FA radioactivity was 
quantified by a Packard TRI-CARB2900TR liquid scintillation analyzer (Packard, 
Meriden, CT, USA). Radioactivity, expressed in counts per mins, was converted to 
disintegration per mins and then to nCi (1 nCi corresponds to 37 Becquerel). Brain PL 
class radioactivity (in nCi/g of brain), the area under the curve of plasma radioactivity (in 
µCi/ml*s), and plasma DHA concentration (in nmol/ml) were then used to calculate a 
brain uptake coefficient of DHA (k*, in µl x s-1 x g of brain-1) and a rate of DHA entry 
(Jin, in nmol x g of brain
-1 x d-1) into each PL class as described previously [9]. Briefly, k* 
for each PL class was calculated with the following equation: 


T
plasma
brain
dtC
TC
k
0
*
)(*
*  
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where C*brain (T) is the radioactivity of the brain PL class at the time of sacrifice and 

T
plasma dtC
0
*  is the integral (area under the curve) of plasma total radioactivity over the 
course of the five mins infusion. The Jin, was calculated by the following equation: 
plasmain CkJ **  
Where C*plasma is the concentration of DHA in the NE plasma pool (for the NE-
14C-DHA 
group) or the lysoPtdCho plasma pool (for the lysoPtdCho-14C-DHA group). For 
calculation of relative radioactivity, brain radioactivity within a specific PL class was 
compared against the brain radioactivity of total PLs and reported as percent of total PL 
radioactivity. Radioactivity controlled for the brain DHA pool or the total FA pool was 
calculated by dividing brain radioactivity within each PL class separately (nCi/g of brain) 
against DHA or total FA concentrations (µmol/g of brain), respectively, in the 
corresponding PL pools. 
2.6. Statistical analyses 
 Radioactivity and kinetics results are expressed as mean ± SEM. The differences 
between the results of the lysoPtdCho-14C-DHA group (n = 4) and the NE-14C-DHA 
group (n = 4) for radioactivity and kinetics results were assessed by nonparametric Mann-
Whitney tests (SPSS statistics 20, IBM Corp., NY, USA). Brain total FA concentrations 
and brain DHA concentrations are reported for the DHA groups together (n = 8). No 
statistical test was performed on these results. Statistical significance was set at p < 0.05.  
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3. Results 
3.1. Radioactivity is higher in brain PtdIns and ChoGpl of lysoPtdCho-14C-DHA infused 
rats than in NE-14C-DHA infused rats. 
In the lysoPtdCho-14C-DHA infused rats, the ChoGpl pool contained the most 
radioactivity (in nCi/g of brain) followed by the EtnGpl pool whereas in NE-14C-DHA 
infused rats, radioactivity was higher in the EtnGpl than in the ChoGpl pool (Fig. 1a). 
There was a significant difference in radioactivity between lysoPtdCho-14C-DHA infused 
rats and NE-14C-DHA infused rats in ChoGpl (1.75 ± 0.11 nCi/g vs 0.53 ± 0.08 nCi/g, 
respectively, p = 0.03) and in PtdIns (0.43 ± 0.03 nCi/g vs 0.26 ± 0.05 nCi/g, respectively, 
p = 0.03) (Fig. 1a). The radioactivity difference between the two groups within the 
ChoGpl pool was driven by the PtdCho pool (1.51 ± 0.10 nCi/g in the lysoPtdCho-14C-
DHA group vs 0.45 ± 0.06 nCi/g in the NE-14C-DHA, p = 0.03). There was no difference 
between the two groups regarding radioactivity in the PlsCho pool (Fig. 1a). 
3.2. Relative to other brain PLs, lysoPtdCho-DHA enriches more of the ChoGpl pool and 
less of the EtnGpl pool compared to NE-DHA.  
The proportion of total PL radioactivity in the lysoPtdCho-14C-DHA group 
compared to the NE-14C-DHA group was significantly higher in ChoGpl (48 ± 2% vs 28 
± 3%, respectively, p = 0.03, Fig. 1b) but lower in EtnGpl (32 ± 1 % vs 46 ± 4%, 
respectively, p = 0.03, Fig. 1b).  
Within the ChoGpl pool, the proportion of total PL radioactivity in PtdCho was 44 
± 2 % in the lysoPtdCho-14C-DHA group compared to 24 ± 3 % in the NE-14C-DHA 
group (p = 0.03, Fig 1b). Within the EtnGpl pool, the proportion of total PL radioactivity 
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in PtdEtn was 26 ± 1 % in the lysoPtdCho-14C-DHA group compared to 36 ± 2 % in the 
NE-14C-DHA group (p = 0.03, Fig 1b). There was no difference between the DHA groups 
regarding the proportion of total PL radioactivity in the PlsCho and PlsEtn pools (Fig 1b). 
3.3. The net rate of DHA entry into brain PL classes is lower from the plasma 
lysoPtdCho pool than from the NE pool. 
 Brain DHA exposure to the infusate was 2.8 times higher in the lysoPtdCho-14C-
DHA group than in the NE-14C-DHA group, as suggested by plasma radioactivity area 
under the curve (35.6 ± 1.5 µCi/ml*s vs 13.3 ± 2.8 µCi/ml*s, respectively, p = 0.03, Fig. 
2a). Compared to the NE-14C-DHA group, the k* in the lysoPtdCho-14C-DHA group was 
50-51% lower for EtnGpl, PtdEtn and PlsEtn (p = 0.03 for all), but similar for PtdIns, 
PtdSer, ChoGpl, PtdCho, PlsCho and ceramide phosphocholine (CerPCho or 
sphingomyelin) (Fig. 2b).  
In the plasma lysoPtdCho pool of the lysoPtdCho-14C-DHA group, DHA 
concentration was 0.92 ± 0.11 nmol/ml whereas it was 2.88 ± 0.32 nmol/ml in the plasma 
NEFA pool of the NE-14C-DHA group. This information was previously reported in [9] 
and was used to calculate Jin (in nmol x g of brain
-1 x d-1, Fig. 2c).  In the lysoPtdCho-
14C-DHA group as compared to the NE-14C-DHA group, Jin was 85% lower into EtnGpl 
(2.62 ± 0.32 vs 16.94 ± 3.22, respectively, p = 0.03), 84% lower into PtdEtn (2.09 ± 0.24 
vs 13.41 ± 2.35, respectively, p = 0.03), 85% lower into PlsEtn (0.53 ± 0.10 vs 3.53 ± 
1.15, respectively, p = 0.03), 83% lower into PtdIns (0.96 ± 0.13 vs 5.50 ± 1.47, 
respectively, p = 0.03), 86% lower into PtdSer (0.27 ± 0.07 vs 1.95 ± 0.36, respectively, p 
= 0.03), 62% lower into ChoGpl (3.85 ± 0.28 vs 10.15 ± 1.60, respectively, p = 0.03), 
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59% lower into PtdCho (3.55 ± 0.27 vs 8.73 ± 1.28, respectively, p = 0.03), 79% lower 
into PlsCho (0.30 ± 0.01 vs 1.42 ± 0.37, respectively, p = 0.03),  and 84% lower into 
CerPCho (0.48 ± 0.22 vs 2.96 ± 1.78, respectively, p = 0.03). 
3.4. LysoPtdCho-DHA enriches more of the ChoGpl pool than NE-DHA after controlling 
for the DHA concentrations within this pool. 
 Similar to previously published manuscripts in rats [10, 17], total FA 
concentrations (in µmol/g of brain) were the highest in ChoGpl (49.26 ± 1.92), followed 
by EtnGpl (32.47 ± 1.44), PtdSer (14.56 ± 0.67), PtdIns (5.05 ± 0.19) and CerPCho (2.57 
± 0.14) (Fig. 3a). DHA concentrations (in µmol/g of brain), however, were the highest in 
EtnGpl (5.30 ± 0.20), followed by PtdSer (2.29 ± 0.11), ChoGpl (1.26 ± 0.07), PtdIns 
(0.20 ± 0.01) and CerGpl (0.02 ± 0.01) (Fig. 3b). Within the EtnGpl pool, approximately 
57 % of DHA was esterified to PtdEtn compared to 43 % esterified to PlsEtn whereas in 
the ChoGpl pool, approximately 92 % of DHA was esterified to PtdCho compared to 8 % 
esterified to PlsCho (Fig 3c). 
 Radioactivity was approximately two-fold higher in the ChoGpl and PtdCho of 
the lysoPtdCho-14C-DHA group compared to the NE-14C-DHA group when controlling 
for DHA concentrations in ChoGpl and PtdCho, respectively (p = 0.03 for both, Fig 4a). 
When controlling for total FA concentrations, radioactivity was also two-fold higher in 
the ChoGpl of the lysoPtdCho-14C-DHA group compared to the NE-14C-DHA group (p = 
0.03, Fig 4b).  
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4. Discussion 
The objective of this study was to evaluate whether plasma lysoPtdCho-DHA 
preferentially targets specific PL of the brain compared to NE-DHA. Our primary finding 
is that lysoPtdCho-14C-DHA was relatively more incorporated into PtdCho within the 
ChoGpl pool and relatively less into PtdEtn within the EtnGpl pool compared to NE-14C-
DHA. These results support the hypothesis that after crossing the blood-brain barrier 
(BBB), a significant portion of lysoPtdCho-DHA undergoes rapid acylation with another 
FA to form PtdCho. NE-DHA, on the other hand, is mostly esterified to ethanolamine to 
form PtdEtn.  It is important to note, however, that after controlling for plasma DHA 
concentration and exposure, the net rate of DHA entry into the brain was significantly 
lower in the lysoPtdCho-14C-DHA group compared to the NE-14C-DHA group for every 
PL class. This confirms findings from our previous report [9] and suggests that the NE-
DHA plasma pool is a quantitatively larger contributor to brain DHA uptake than the 
lysoPtdCho-DHA pool. 
De novo PL biosynthesis within the brain is a tightly regulated process. PL 
synthesis occurs in the endoplasmic reticulum with the two most abundant PL classes in 
the brain being PtdCho and PtdEtn. The main synthesis pathway of PtdCho and PtdEtn is 
believed to be through diacylglycerol association with cytidine diphosphate choline or 
cytidine diphosphate ethanolamine, respectively [18, 19] (Fig. 3). This pathway is known 
as the Kennedy pathway [20]. Another contributor to PtdCho and PtdEtn synthesis is 
through acylation of lysoPtdCho and lysophosphatidylethanolamine (lysoPtdEtn), 
respectively (Fig. 3). PL synthesis from the lyso pool is catalysed by a family of enzyme 
called 1-acylglycerol-3-phosphate-O-acyltransferases [21] (Fig. 3), but the contribution 
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of these pools to the synthesis of PtdCho and PtdEtn in vivo in the brain is not clear. Our 
results suggest that lysoPtdCho-DHA tends to be preferentially reacylated to form 
PtdCho with less being deacylated to form NE-DHA which could then enter the Kennedy 
pathway. It also supports the hypothesis that a significant portion of lysoPtdCho-DHA 
might be transported intact across the BBB and that this passage likely would require a 
transporter such as Mfsd2a as suggested by other investigators [22, 23] (Fig. 3). 
However, we detected radioactivity in the brain diacylglycerol, NE-FA and 
triacylglycerol combined pool of the lysoPtdCho-14C-DHA infused rats suggesting that 
some lysoPtdCho-DHA is deacylated within five mins (data not shown). On the other 
hand, NE-14C-DHA mostly went through the Kennedy pathway or was associated with 
lysoPtdCho or lysoPtdEtn to form PtdCho and PtdEtn (Fig. 3), but the relative 
contribution of either of these pathways cannot be evaluated here. 
The results reported here for brain radioactivity after infusion of NE-14C-DHA are 
similar to previous reports [11, 24], but there are some differences with regards to the 
results for lysoPtdCho-14C-DHA [24]. Thies et al. reported that 2.5 mins after a single 
bolus iv infusion of lysoPtdCho-14C-DHA in rats, radioactivity was similar between the 
EtnGpl pool and the ChoGpl pool, but that EtnGpl was the main radioactive pool 30 mins 
after the infusion [24]. These results support our hypothesis that lysoPtdCho-DHA 
preferentially incorporates into PtdCho when compared to NE-DHA, but that reacylation 
from PtdCho to PtdEtn might be a significant contributor to PtdCho turnover. However, 
in our previous report related to this study, radioactivity in the lysoPtdCho pool 
represented only 31% of plasma total lipid radioactivity 30 mins after iv bolus infusion of 
lysoPtdCho-14C-DHA [9]. This suggests that at that time point, a significant proportion of 
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brain exposure to plasma DHA is not from the lysoPtdCho-DHA pool and thus 
comparisons between iv bolus and the five mins iv protocol performed here are difficult 
to make. 
The transporter-mediated passage of lysoPtdCho-DHA across the BBB might be 
an important contributor to brain choline enrichment. Most choline transport across the 
BBB is believed to be through facilitated diffusion of free choline although specific 
transporters with various affinities have been identified [25-27]. The Jin of free choline 
has been estimated by at least two methods; in situ rat brain perfusions [27] or the Braun 
method in vivo [28-31]. From these studies, we estimate that under normal physiological 
plasma concentrations (10 µM), the free choline Jin would be 300-600 nmol/g of brain/d 
[27, 29-31]. Here, we observed that the Jin for lysoPtdCho-DHA into brain total PLs is 
about 8 nmol/g of brain/d, but only approximately 1% of plasma lysoPtdCho is acylated 
with DHA [32, 33] and thus uptake of total lysoPtdCho could be a significant contributor 
to brain choline enrichment. This is based on the assumption that the vast majority of 
choline within lysoPtdCho enters the brain with lysoPtdCho and this is supported by a 
previous study [24], but also that all lysoPtdCho species enter the brain. However, it has 
been reported that lysoPtdCho acylated with monounsaturates and polyunsaturates are 
more efficient for enriching the brain than lysoPtdCho-palmitate [34] and we believe that 
this could be due to a higher affinity of Mfsd2a for mono- and polyunsaturates than for 
saturates [35]. Moreover, we need to be cautious with the comparison between the 
lysoPtdCho-DHA Jin reported here vs the choline Jin reported by the other investigators 
[27, 29, 31] since the methods used to quantify Jin are not the same between the studies. 
Nonetheless, the question of whether the lysoPtdCho pool is a significant contributor to 
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brain choline uptake merits further investigation because this could be important for 
developing therapies for patients with MFSD2A mutations [35, 36]. 
Both DHA forms were found to significantly enrich the brain PtdIns pool; 
radioactivty in the PtdIns represented approximately 13% of total PL radioactivity in both 
groups. PtdIns is synthesised with diacylglycerol as a substrate in a one-step process [37] 
(Fig. 5). Interestingly, PtdIns is the smallest pool of brain PLs, representing only 5% of 
total PL FA concentrations and <3% of DHA concentration and this is in accordance to 
previously published reports in both humans [6] and rats [10, 17]. PtdIns is an important 
signaling molecule as it serves, notably, as a substrate for phophatidylinositol bis- and 
trisphosphates. These molecules are crucial in the regulation of cell growth and survival 
through, in part, the PI3K-PKB/Akt pathway [38]. Therefore, PtdIns turnover might be 
more rapid than other phospholipids and most DHA-containing PtdIns detected after the 
five mins iv infusion could serve as substrates to enter the PI3K-PKB/Akt pathway. A 
previous study reported that the DHA half-life in the PtdIns and ChoGpl pools is 27.3% 
and 30.3% shorter, respectively, than in the total PL pool [39]. This could explain the 
apparent discrepancy between the results we report here for radioactivity into the PtdIns 
and ChoGpl pools vs the DHA concentration within these pools. Moreover, previous 
studies report similar results to what is reported here with regards to the relative 
distribution of k* and DHA in the PtdIns and ChoGpl pools compared to the other PL 
pools five mins after iv infusion with NE-
14
C-DHA [17, 40]. 
In this study, the smallest PL pool of radioactivity was PtdSer (3-5% of total PL 
radioactivity) whereas this pool was the second most enriched with DHA. DHA-
containing PtdSer are believed to be critical for cell survival and differentiation in 
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addition to regulating the PI3K-PKB/Akt pathway [7, 8]. However, in humans and 
animals, PtdSer cannot be synthesised de novo; it is formed by base exchange with either 
PtdEtn or PtdCho [41]. Therefore, the turnover of DHA in the PtdSer pool might be 
longer than in other PL pools as previously suggested [11, 39] and this would explain 
why low levels of radioactivity were detected in PtdSer relative to EtnGpl, ChoGpl and 
PtdIns after five mins iv infusion of DHA. 
In support of the primary study related to this manuscript [9], we report that the 
lysoPtdCho-14C-DHA infused animals had significantly more brain radioactivity than the 
NE-14C-DHA infused animals, but this was specific to the PtdIns and ChoGpl pools. 
These results are mostly attributable to a higher DHA plasma exposure in the 
lysoPtdCho-14C-DHA group compared to the NE-14C-DHA group. This is attributed to 
the lysoPtdCho-DHA having a approximately 20-fold longer plasma half-life compared 
to NE-DHA [9]. 
In summary, we report that after a five mins iv infusion, lysoPtdCho-14C-DHA 
preferentially incorporates into ChoGpl and less into EtnGpl compared to NE-14C -DHA. 
These findings suggest that lysoPtdCho-DHA might selectively enrich certain types of PL 
within the ChoGpl pool, contributing to brain choline homeostasis. Both forms of DHA 
were found to significantly enrich the PtdIns pool which was surprising considering the 
relatively low DHA concentrations within this pool. In the future, it will be relevant to 
assess whether chronic feeding with PC-DHA could result in similar PL class-specific 
brain enrichment to what is reported here for lysoPtdCho-DHA.  
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Fig. legends 
Fig. 1: (a) Whole brain and (b) relative radioactivity in the EtnGpl, PtdIns, PtdSer, 
CholGpl and CerPCho pools of rats iv infused over five mins with either NE-
14
C-DHA or 
lysoPtdCho-14C-DHA (n = 4 per group).  Differences between the DHA groups’ results 
were assessed by nonparametric Mann-Whitney tests. * p < 0.05. CerPCho, ceramide 
phosphocholine or sphingomyelin; ChoGpl, choline glycerophospholipid; EtnGpl, 
ethanolamine glycerophospholipid; lysoPtdCho-14C-DHA, lysophosphatidylcholine 
docosahexaenoic acid radiolabelled with carbon 14 [1-14C]; NE-14C-DHA, non-esterified 
docosahexaenoic acid radiolabelled with carbon 14 [1-14C]; PlsCho, plasmenylcholine; 
PlsEtn, plasmenylethanolamine; PtdCho, phosphatidylcholine; PtdEtn, 
phosphatidylethanolamine; PtdIns, phosphatidylinositol; PtdSer, phophatidylserine. 
 
Fig. 2: (a) Total plasma radioactivity area under the curve over five mins, (b) DHA 
uptake coefficient (k*), and (c) net rate of DHA entry (Jin) in the EtnGpl, PtdIns, PtdSer, 
CholGpl and CerPCho pools of rats iv infused over five mins with either NE-
14
C-DHA or 
lysoPtdCho-14C-DHA (n = 4 per group).  Differences between the DHA groups’ results 
were assessed by nonparametric Mann-Whitney tests. * p < 0.05. CerPCho, ceramide 
phosphocholine or sphingomyelin; ChoGpl, choline glycerophospholipid; EtnGpl, 
ethanolamine glycerophospholipid; lysoPtdCho-14C-DHA, lysophosphatidylcholine 
docosahexaenoic acid radiolabelled with carbon 14 [1-14C]; NE-14C-DHA, non-esterified 
docosahexaenoic acid radiolabelled with carbon 14 [1-14C]; PlsCho, plasmenylcholine; 
PlsEtn, plasmenylethanolamine; PtdCho, phosphatidylcholine; PtdEtn, 
phosphatidylethanolamine; PtdIns, phosphatidylinositol; PtdSer, phophatidylserine. 
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Fig. 3: Whole brain (a) total FA concentrations and (b) DHA concentrations in the 
EtnGpl, PtdIns, PtdSer, CholGpl and CerPCho pools of rats iv infused over five mins 
with either NE-
14
C-DHA or lysoPtdCho-14C-DHA (n = 4 per group). DHA plasmalogen 
repartition within the EtnGpl pool and the ChoGpl pool is shown in (c). CerPCho, 
ceramide phosphocholine or sphingomyelin; ChoGpl, choline glycerophospholipid; 
EtnGpl, ethanolamine glycerophospholipid; FA, fatty acid; lysoPtdCho-14C-DHA, 
lysophosphatidylcholine docosahexaenoic acid radiolabelled with carbon 14 [1-14C]; NE-
14
C-DHA, non-esterified docosahexaenoic acid radiolabelled with carbon 14 [1-14C]; 
PlsCho, plasmenylcholine; PlsEtn, plasmenylethanolamine; PtdCho, phosphatidylcholine; 
PtdEtn, phosphatidylethanolamine; PtdIns, phosphatidylinositol; PtdSer, 
phophatidylserine. 
Fig 4: Whole brain radioactivity controlled for (a) DHA concentrations and (b) total FA 
concentrations in the EtnGpl, PtdIns, PtdSer, CholGpl and CerPCho pools of rats iv 
infused over five mins with either NE-
14
C-DHA or LPC-
14
C-DHA (n = 4 per group). 
Differences between the DHA groups’ results were assessed by nonparametric Mann-
Whitney tests. * p < 0.05.  CerPCho, ceramide phosphocholine or sphingomyelin; 
ChoGpl, choline glycerophospholipid; EtnGpl, ethanolamine glycerophospholipid; FA, 
fatty acid; LPC-14C-DHA, lysophosphatidylcholine docosahexaenoic acid radiolabelled 
with carbon 14 [1-14C]; NE-14C-DHA, non-esterified docosahexaenoic acid radiolabelled 
with carbon 14 [1-14C]; PlsCho, plasmenylcholine; PlsEtn, plasmenylethanolamine; 
PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine; PtdIns, 
phosphatidylinositol; PtdSer, phophatidylserine. 
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Fig. 5: Schematic representation of glycerophospholipid biosynthesis within the brain. 
The proposed lysoPtdCho-DHA pathways follow the red arrows whereas the proposed 
NE-DHA pathways follow the green arrows. After being transported across the BBB 
through the Mfsd2a transporter, our results suggest that most of lysoPtdCho-DHA is 
rapidly incorporated into the PtdCho pool, supporting the hypothesis that a portion of 
lysoPtdCho-DHA crosses the BBB intact. DHA can be released from lysoPtdCho or from 
PtdCho to be converted to DHA-CoA and esterified to other PLs, notably to PtdEtn via 
the Kennedy pathway or to PtdIns via a one-step reaction involving CDP-DGA. NE-
DHA is believed to cross the BBB through passive diffusion before being converted to 
DHA-CoA. Some DHA-CoA is used for DAG formation which is then esterified to either 
PtdEtn or PtdChol via the Kennedy pathway. The synthesis of PtdSer is performed by 
base exchange with either PtdEtn or PtdChol via PSS2 or PSS1, respectively. It is 
important to note that some DHA-CoA can also contribute to the formation of 
plasmalogens (gold arrow) which represent a significant proportion of brain choline and 
ethanolamine glycerophospholipids. Moreover, there are quantifiable concentrations of 
lysoPtdOH, lysoPtdCho, lysoPtdEtn, lysoPtdIns and lysoPtdSer inside the brain which 
can serve as substrates for the synthesis of PtdOH, PtdCho, PtdEtn, PtdIns and PtdSer, 
respectively (blue arrows). These reactions are catalysed by a family of enzymes called 
AGPATs but the contribution of these to brain PL synthesis is unknown. AGPATs, 1-
acylglycerol-3-phosphate-O-acyltransferases; BBB, blood-brain barrier; CDP, cytidine 
diphosphate; CerPCho, ceramide phosphocholine or sphingomyelin; CoA, coenzyme A; 
DAG, diacylglycerol; DHA, docosahexaenoic acid; Ins, inositol; LPLATs, 
lysophospholipid acyltransferases; LysoPtdCho, lysophosphatidylcholine; LysoPtdEtn, 
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lysophosphatidylethanolamine; LysoPtdIns, lysophophatidylinositol; LysoPtdOH, 
lysophosphatidic acid; LysoPtdSer, lysophosphatidylserine; Mfsd2a, major facilitator 
superfamily domain-containing protein 2; NE, non-esterified; PtdCho, 
phosphatidylcholine; PtdEtn, phosphatidylethanolamine; PtdIns, phosphatidylinositol; 
PtdOH, phosphatidic acid; PtdSer, phosphatidylserine; PSS, phosphatidylserine synthase; 
TAG, triacylglycerol. 
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Highlights 
 LysoPtdCho-DHA selectively enriches brain cholineglycerophospholipids. 
 Uptake of lysoPtdCho-DHA into the brain might contribute to brain choline 
enrichment. 
 The net rate of DHA entry into the brain from the plasma lysoPtdCho pool is 
lower than from the NE pool. 
 Brain radioactivity from lysoPtdCho-14C-DHA infused rats is higher than from 
NE-
14
C-DHA infused rats. 
